OncoMatch/Clinical Trials/NCT06315010
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
Official title: A Phase II Study Assessing Safety and Efficacy of Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis (The REPOSE Study)
Is NCT06315010 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies Repotrectinib for nsclc.
Treatment: Repotrectinib — REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ROS1 rearrangement
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
WBC > 3.0 x 10^9/L, ANC ≥ 1.5 x 10^9/L, platelet count ≥ 100.0 x10^9/L, hemoglobin ≥ 8.0 g/dL (≥ 4.96 mmol/L)
Kidney function
serum creatinine ≤ 1.5x ULN or creatinine clearance ≥ 40 mL/min/1.73 m2 (Cockcroft-Gault)
Liver function
Total bilirubin ≤ 1.5x ULN (≤ 3 in patients with liver metastases or Gilbert's disease); ALP ≤ 2.5x ULN; AST/ALT ≤ 3x ULN (≤ 5 in patients with liver metastases); INR < 1.5
Cardiac function
LVEF ≥ 50% by ECHO or MUGA scan
Patient has adequate bone marrow, liver, and renal function: ... see full criterion 16. LVEF ≥ 50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06315010 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ROS1?
Yes, ROS1 rearrangement is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify